Toxicity and Immunogenicity of Enterotoxigenic Escherichia coli Heat-Labile and Heat-Stable Toxoid Fusion 3xSTaA14Q-LTS63K/R192G/L211A in a Murine Model

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Zhang, Chengxian ^a   Knudsen, David E ^a   Liu, Mei ^a,c   Robertson, Donald C ^b   Zhang, Weiping ^a  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

^c HUAZHONG AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT LABILE HEAT STABLE TOXIN TYPE 1B TOXOID FUSION; NEUTRALIZING ANTIBODY; TOXIN ANTIBODY; TOXOID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENTEROTOXIGENIC ESCHERICHIA COLI; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INFECTIOUS DIARRHEA; MOUSE; MULTICENTER STUDY; NONHUMAN; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; ENTEROTOXIGENIC ESCHERICHIA COLI; ENTEROTOXINS; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; MICE; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; SEQUENCE ALIGNMENT; TOXOIDS;

EID: 84885402756     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077386     Document Type: Article

References (44)

1. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, et al. (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375: 1969-1987. doi:10.1016/S0140-6736(10)60549-1. PubMed: 20466419.
2. WHO (2006) Future directions for research on enterotoxigenic Escherichia coli vaccines for developing countries. Wkly Epidemiol Rec 81: 97-107. PubMed: 16671213.
3. WHO (1999) The World. Health Rep: pp. 1999: Making a Difference. Geneva: WHO.
4. DuPont HL, (2008) Systematic review: prevention of travellers' diarrhoea. Alimen. Pharmacol Ther 27: 741-751.
5. Sanders JW, Putnam SD, Riddle MS, Tribble DR, (2005) Military importance of diarrhea: lessons from the Middle East. Curr Opin Gastroenterol 21: 9-14. PubMed: 15687878.
6. Wennerås C, Erling V, (2004) Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world. J Health Popul Nutr 22: 370-382. PubMed: 15663170.
7. Gaastra W, Svennerholm AM, (1996) Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Tren Microbiol 4: 444-452. doi:10.1016/0966-842X(96)10068-8. PubMed: 8950814.
8. Nataro JP, Kaper JB, (1998) Diarrheagenic Escherichia coli. Clin Microbiol Rev 11: 142-201. PubMed: 9457432.
9. Svennerholm AM, (2011) From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development. Indian J Med Res 133: 188-196. PubMed: 21415493.
10. Zhang W, Sack DA, (2012) Progress and hurdles in the development of vaccines against enterotoxigenic Escherichia coli in humans. Expert Rev Vaccines 11: 677-694. doi:10.1586/erv.12.37. PubMed: 22873126.
11. Laurelle L, (1889) L'Etude bacteriologique sur les peritonites par perforation. Cellule 5: 60-123.
12. Boedeker EC, (2005) Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 21: 15-19. PubMed: 15687879.
13. Walker RI, (2005) New vaccines against enteric bacteria for children in less developed countries. Expert Rev Vaccines 4: 807-812. doi:10.1586/14760584.4.6.807. PubMed: 16372876.
14. Frantz JC, Mellencamp MW, (1983) Production and testing of Escherichia coli (LTb) toxoid. In: Acres S, eds. Saskatchewan, Canada: Saskatoon. pp. pp. 500-517.
15. Frantz JC, Robertson DC, (1981) Immunological properties of Escherichia coli heat-stable enterotoxins: development of a radioimmunoassay specific for heat-stable enterotoxins with suckling mouse activity. Infect Immun 33: 193-198. PubMed: 6167519.
16. Taxt A, Aasland R, Sommerfelt H, Nataro J, Puntervoll P, (2010) Heat-stable enterotoxin of enterotoxigenic Escherichia coli as a vaccine target. Infect Immun 78: 1824-1831. doi:10.1128/IAI.01397-09. PubMed: 20231404.
17. Zhang W, Zhang C, Francis DH, Fang Y, Knudsen D, et al. (2010) Genetic fusions of heat-labile (LT) and heat-stable (ST) toxoids of porcine enterotoxigenic Escherichia coli elicit neutralizing anti-LT and anti-STa antibodies. Infect Immun 78: 316-325. doi:10.1128/IAI.00497-09. PubMed: 19858307.
18. Clements JD, (1990) Construction of a nontoxic fusion peptide for immunization against Escherichia coli strains that produce heat-labile and heat-stable enterotoxins. Infect Immun 58: 1159-1166. PubMed: 2182535.
19. Klipstein FA, Engert RF, Clements JD, (1982) Development of a vaccine of cross-linked heat-stable and heat-labile enterotoxins that protects against Escherichia coli producing either enterotoxin. Infect Immun 37: 550-557. PubMed: 6749682.
20. Sanchez J, Hirst TR, Uhlin BE, (1988) Hybrid enterotoxin LTA::STa proteins and their protection from degradation by in vivo association with B-subunits of Escherichia coli heat-labile enterotoxin. Gene 64: 265-275. doi:10.1016/0378-1119(88)90341-1. PubMed: 2841198.
21. Svennerholm AM, Holmgren J, (1992) Immunity to enterotoxin-producing bacteria. In: MacDonald TT, eds. Immunology of gastrointestinal diseases. Dordrecht, The Netherlands: Kluwer Publishing House Academic Publishers. pp. pp. 227-246.
22. Liu M, Ruan X, Zhang C, Lawson SR, Knudsen DE, et al. (2011) Heat-labile- and heat-stable-toxoid fusions (LTRG-STaPF) of human enterotoxigenic Escherichia coli elicit neutralizing antitoxin antibodies. Infect Immun 79: 4002-4009. doi:10.1128/IAI.00165-11. PubMed: 21788385.
23. Liu M, Zhang C, Mateo K, Nataro JP, Robertson DC, et al. (2011) Modified Heat-Stable Toxins (hSTa) of Enterotoxigenic Escherichia coli Lose Toxicity but Display Antigenicity after Being Genetically Fused to Heat-Labile Toxoid LT. ToxinsVolumes R192G: 3: 1146-1162.
24. Ausubel FM, Brent R, Kingston RK, Moore DD, Seidman JG, Smith JA, Struhl K, (1999) Short Protocols in molecular biology. New York, NY: John Wiley & Sons, Inc.
25. Ruan X, Liu M, Casey TA, Zhang W, (2011) A tripartite fusion, FaeG-FedF-LT(192)A2:B, of enterotoxigenic Escherichia coli (ETEC) elicits antibodies that neutralize cholera toxin, inhibit adherence of K88 (F4) and F18 fimbriae, and protect pigs against K88ac/heat-labile toxin infection. Clin. Vaccine Immun 18: 1593-1599.
26. Council NR, (1996) Guide for the care and use of laboratory animals. Washington DC: National Academy Press.
27. Zhang W, Robertson DC, Zhang C, Bai W, Zhao M, et al. (2008) Escherichia coli constructs expressing human or porcine enterotoxins induce identical diarrheal diseases in a piglet infection model. Appl Environ Microbiol 74: 5832-5837. doi:10.1128/AEM.00893-08. PubMed: 18658289.
28. Qadri F, Das SK, Faruque AS, Fuchs GJ, Albert MJ, et al. (2000) Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol 38: 27-31. PubMed: 10618058.
29. Wolf MK, (1997) Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin Microbiol Rev 10: 569-584. PubMed: 9336662.
30. Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, et al. (2007) Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25: 4392-4400. doi:10.1016/j.vaccine.2007.03.034. PubMed: 17448578.
31. Lewis DJ, Huo Z, Barnett S, Kromann I, Giemza R, et al. (2009) Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLOS ONE 4: e6999. doi:10.1371/journal.pone.0006999. PubMed: 19756141.
32. Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H, (2001) Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol 53: 211-217. doi:10.1046/j.1365-3083.2001.00883.x. PubMed: 11251876.
33. Datta SK, Sabet M, Nguyen KP, Valdez PA, Gonzalez-Navajas JM, et al. (2010) Mucosal adjuvant activity of cholera toxin requires Th17 cells and protects against inhalation anthrax. Proc Natl Acad Sci U S A 107: 10638-10643. doi:10.1073/pnas.1002348107. PubMed: 20479237.
34. Joensuu JJ, Verdonck F, Ehrström A, Peltola M, Siljander-Rasi H, et al. (2006) F4 (K88) fimbrial adhesin FaeG expressed in alfalfa reduces F4+ enterotoxigenic Escherichia coli excretion in weaned piglets. Vaccine 24: 2387-2394. doi:10.1016/j.vaccine.2005.11.056. PubMed: 16378664.
35. Delisle B, Calinescu C, Mateescu MA, Fairbrother JM, Nadeau E, (2012) Oral immunization with f4 fimbriae and CpG formulated with carboxymethyl starch enhances f4-specific mucosal immune response and modulates Th1 and th2 cytokines in weaned pigs. J Pharm Pharm Sci 15: 642-656. PubMed: 23331903.
36. Olvera-Gomez I, Hamilton SE, Xiao Z, Guimaraes CP, Ploegh HL, et al. (2012) Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination. Proc Natl Acad Sci U S A 109: 2072-2077. doi:10.1073/pnas.1105771109. PubMed: 22308317.
37. Jackson EM, Herbst-Kralovetz MM, (2012) Intranasal vaccination with murabutide enhances humoral and mucosal immune responses to a virus-like particle vaccine. PLOS ONE 7: e41529. doi:10.1371/journal.pone.0041529. PubMed: 22855691.
38. Kurono Y, Miyashita K, Makise T, Nagano H, (2011) Diversity of mucosal immune responses in upper respiratory organs and its application for mucosal vaccine. Adv Otorhinolaryngol 72: 146-148. PubMed: 21865715.
39. Andrew DW, Hafner LM, Beagley KW, Timms P, (2011) Partial protection against chlamydial reproductive tract infection by a recombinant major outer membrane protein/CpG/cholera toxin intranasal vaccine in the guinea pig Chlamydia caviae model. J Reprod Immunol 91: 9-16. doi:10.1016/j.jri.2011.06.100. PubMed: 21856018.
40. Amuguni JH, Lee S, Kerstein KO, Brown DW, Belitsky BR, et al. (2011) Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine 29: 4778-4784. doi:10.1016/j.vaccine.2011.04.083. PubMed: 21565244.
41. Cho HJ, Kim JY, Lee Y, Kim JM, Kim YB, et al. (2010) Enhanced humoral and cellular immune responses after sublingual immunization against human papillomavirus 16 L1 protein with adjuvants. Vaccine 28: 2598-2606. doi:10.1016/j.vaccine.2010.01.013. PubMed: 20116467.
42. Cuburu N, Kweon MN, Song JH, Hervouet C, Luci C, et al. (2007) Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25: 8598-8610. doi:10.1016/j.vaccine.2007.09.073. PubMed: 17996991.
43. Czerkinsky C, Cuburu N, Kweon MN, Anjuere F, Holmgren J, (2011) Sublingual vaccination. Hum Vaccin 7: 110-114. doi:10.4161/hv.7.1.13739. PubMed: 21263223.
44. Negri DR, Riccomi A, Pinto D, Vendetti S, Rossi A, et al. (2010) Persistence of mucosal and systemic immune responses following sublingual immunization. Vaccine 28: 4175-4180. doi:10.1016/j.vaccine.2010.04.013. PubMed: 20412876.